GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (FRA:CBO) » Definitions » Notes Receivable

Imunon (FRA:CBO) Notes Receivable : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Imunon Notes Receivable?

Imunon's Notes Receivable for the quarter that ended in Sep. 2024 was €0.00 Mil.


Imunon Notes Receivable Historical Data

The historical data trend for Imunon's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Notes Receivable Chart

Imunon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Imunon Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Imunon Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Imunon Notes Receivable Related Terms

Thank you for viewing the detailed overview of Imunon's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon Business Description

Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Imunon Headlines

No Headlines